171 related articles for article (PubMed ID: 30400893)
1. Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.
Berman J; Brown T; Dow G; Toovey S
Malar J; 2018 Nov; 17(1):407. PubMed ID: 30400893
[TBL] [Abstract][Full Text] [Related]
2. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.
Elmes NJ; Nasveld PE; Kitchener SJ; Kocisko DA; Edstein MD
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1095-101. PubMed ID: 18541280
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine: First Global Approval.
Frampton JE
Drugs; 2018 Sep; 78(14):1517-1523. PubMed ID: 30229442
[TBL] [Abstract][Full Text] [Related]
5. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
6. Tafenoquine for the treatment of
Llanos-Cuentas A; Manrrique P; Rosas-Aguirre A; Herrera S; Hsiang MS
Expert Opin Pharmacother; 2022 May; 23(7):759-768. PubMed ID: 35379070
[TBL] [Abstract][Full Text] [Related]
7. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S; Rodrigo C; Fernando SD
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
[TBL] [Abstract][Full Text] [Related]
8. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
9. Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.
Duparc S; Chalon S; Miller S; Richardson N; Toovey S
Malar J; 2020 Mar; 19(1):111. PubMed ID: 32169086
[TBL] [Abstract][Full Text] [Related]
10. Cost-Benefit Analysis of Tafenoquine for Radical Cure of
Suh J; Kim JH; Kim JD; Kim C; Choi JY; Lee J; Yeom JS
J Korean Med Sci; 2022 Jul; 37(27):e212. PubMed ID: 35818703
[TBL] [Abstract][Full Text] [Related]
11. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
[TBL] [Abstract][Full Text] [Related]
13. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
Anjum MU; Naveed AK; Mahmood SN; Naveed OK
Travel Med Infect Dis; 2020; 36():101576. PubMed ID: 32036012
[TBL] [Abstract][Full Text] [Related]
14. Tafenoquine for travelers' malaria: evidence, rationale and recommendations.
Baird JK
J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30380095
[TBL] [Abstract][Full Text] [Related]
15. Tafenoquine: a toxicity overview.
Chu CS; Hwang J
Expert Opin Drug Saf; 2021 Mar; 20(3):349-362. PubMed ID: 33306921
[No Abstract] [Full Text] [Related]
16. Tafenoquine: the new kid on the block.
Chen V; Daily JP
Curr Opin Infect Dis; 2019 Oct; 32(5):407-412. PubMed ID: 31305490
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine, isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.
SCHMIDT IG; SCHMIDT LH
J Neuropathol Exp Neurol; 1951 Jul; 10(3):231-56. PubMed ID: 14861663
[No Abstract] [Full Text] [Related]
18. Cost-Effectiveness Analysis of Sex-Stratified
Devine A; Howes RE; Price DJ; Moore KA; Ley B; Simpson JA; Dittrich S; Price RN
Am J Trop Med Hyg; 2020 Jul; 103(1):394-403. PubMed ID: 32372747
[TBL] [Abstract][Full Text] [Related]
19. Tafenoquine for
Sharma J; Gautam CS; Singh H; Singh J
Indian J Med Res; 2021 Jun; 154(6):797-805. PubMed ID: 35662084
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.
Nasveld P; Kitchener S; Edstein M; Rieckmann K
Trans R Soc Trop Med Hyg; 2002; 96(6):683-4. PubMed ID: 12625150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
